In Phase III trials evaluating VEGF and mTOR inhibitors, the most common grade 3 and 4 AEs observed including hypertension, decreased left ventricular ejection fraction, hand-foot-syndrome and myelosuppression [16]. This evidence concerns the gene MTOR and Hypertension.